A deadline set by pharmaceutical manufacturer Eli Lilly for hospitals to submit claims-level data under the federal 340B Drug Pricing Program has passed, leaving some providers at risk of losing access to discounted drug pricing.
Lilly first announced in January that it would begin enforcing a policy requiring the submission